0A8D Stock Overview
A clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TNF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.25 |
| 52 Week High | US$9.92 |
| 52 Week Low | US$1.15 |
| Beta | 2.67 |
| 11 Month Change | -32.36% |
| 3 Month Change | -34.01% |
| 1 Year Change | -85.55% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8D | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 8.7% | -2.3% | 0.8% |
| 1Y | -85.6% | -2.7% | 6.6% |
Return vs Industry: 0A8D underperformed the UK Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: 0A8D underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| 0A8D volatility | |
|---|---|
| 0A8D Average Weekly Movement | 21.4% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A8D's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A8D's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 6 | n/a | tnfpharma.com |
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.
TNF Pharmaceuticals, Inc. Fundamentals Summary
| 0A8D fundamental statistics | |
|---|---|
| Market cap | US$3.39m |
| Earnings (TTM) | -US$28.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 0A8D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8D income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.92m |
| Earnings | -US$28.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0A8D perform over the long term?
See historical performance and comparison